| breast cancer - adjuvant | breast cancer - HER2-positive | breast cancer - HR positive | |||
| breast cancer - adjuvant | es-BC - HER2 positive - (neo)adjuvant (NA) | la/mBC - HER2 positive - 1st Line (L1) | la/mBC - HER2 positive - 2nd Line (L2) | la/mBC - HR-positive - 1st line (L1) | |
| HER2 inhibitor | |||||
| neratinib based treatment | |||||
| neratinib | ExteNET | ExteNET | |||
| neratinib plus capecitabine | NALA NALA ... | ||||
| pertuzumab based treatment | |||||
| pertuzumab plus trastuzumab | APHINITY | ||||
| pertuzumab plus trastuzumab plus docetaxel | CLEOPATRA | ||||
| trastuzumab based treatment | |||||
| docetaxel plus carboplatin with trastuzumab followed by trastuzumab | |||||
| doxorubicin plus cyclophosphamide followed by docetaxel plus trastuzumab | |||||
| trastuzumab plus endocrine therapy | SYSUCC-002 | SYSUCC-002 | |||
| trastuzumab plus epirubicin and cyclophosphamide followed by docetaxel | |||||
| tucatinib based treatment | |||||
| tucatinib plus trastuzumab plus capecitabine | HER2CLIMB HER2CLIMB ... | ||||